PHARMACOKINETICS OF TILMOVET~R 200 MG/G PREMIX IN PIGS APPLIED ORALLY AND ITS BIOEQUIVALENCE WITH PULMOTIL G 200 PREMIX

摘要

The aim of the study was to investigate the pharmacokinetics of a new tilmicosin (TMS) premix formulation applied orally to pigs as Tilmovet 200 mg/g (Huvepharma NV) and its bioequivalence to Pulmotil G 200 (E. Lilly, Elanco) (PUL). Two groups of 10 pigs each (Danube White) equally male and female (9-14.45 kg), 9-10 weeks of age, were used. TMS at a dose of 16 mg/kg as Tilmovet* 200 mg/g premix was applied in group I. The same dose of PUL was administered to group II. Blood was taken at predetermined intervals up to 192nd h and TMS plasma concentrations were analyzed by a validated HPLC method. Basic pharmacokinetic (PK) parameters of both products were calculated by a two-compartment PK model. Bioequivalence was assessed using parallel design test suitable for experiments with growing animals (1).